Altered cellular metabolism, including an increased dependence on aerobic glycolysis, is a hallmark of cancer. Despite the fact that this observation was first made nearly a century ago, effective therapeutic targeting of glycolysis in cancer has remained elusive. One potentially promising approach involves targeting the glycolytic enzyme lactate dehydrogenase (LDH), which is overexpressed and plays a critical role in several cancers. Here, we used a novel class of LDH inhibitors to demonstrate, for the first time, that Ewing sarcoma cells are exquisitely sensitive to inhibition of LDH. EWS-FLI1, the oncogenic driver of Ewing sarcoma, regulated LDH A (LDHA) expression. Genetic depletion of LDHA inhibited proliferation of Ewing sarcoma cells and induced apoptosis, phenocopying pharmacologic inhibition of LDH. LDH inhibitors affected Ewing sarcoma cell viability both in vitro and in vivo by reducing glycolysis. Intravenous administration of LDH inhibitors resulted in the greatest intratumoral drug accumulation, inducing tumor cell death and reducing tumor growth. The major dose-limiting toxicity observed was hemolysis, indicating that a narrow therapeutic window exists for these compounds. Taken together, these data suggest that targeting glycolysis through inhibition of LDH should be further investigated as a potential therapeutic approach for cancers such as Ewing sarcoma that exhibit oncogene-dependent expression of LDH and increased glycolysis. Significance: LDHA is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma.
NAMPT mediates the rate-limiting step of the NAD salvage pathway, which maintains cellular bioenergetics and provides a necessary substrate for functions essential to rapidly proliferating cancer cells. In this study, we evaluated the efficacy and mechanisms of action of OT-82, a novel, high-potency NAMPT inhibitor with a favorable toxicity profile, in preclinical models of Ewing sarcoma (EWS), an aggressive pediatric malignancy with previously reported selective sensitivity to NAMPT inhibition. We show that OT-82 decreased NAD concentration and impaired proliferation of EWS cells in a dose-dependent manner, with IC50values in the single-digit nanomolar range. Notably, genetic depletion of NAMPT phenocopied pharmacological inhibition. On-target activity of OT-82 was confirmed with the addition of NMN, the product of NAMPT, which rescued NAD concentration and EWS cellular viability. Mechanistically, OT-82 treatment resulted in impaired DNA damage repair through loss of PARP activity, G2 cell-cycle arrest, and apoptosis in EWS cells. Additional consequences of OT-82 treatment included reduction of glycolytic and mitochondrial activity. In vivo, OT-82 impaired tumor growth and prolonged survival in mice bearing EWS xenografts. Importantly, antitumor effect correlated with pharmacodynamic markers of target engagement. Furthermore, combining low-dose OT-82 with low doses of agents augmenting DNA damage demonstrated enhanced antitumor activity in vitro and in vivo. Thus, OT-82 treatment represents a potential novel targeted approach for the clinical treatment of EWS.
Hormone receptor-positive breast cancer (HR + BC) responds well to neoadjuvant endocrine therapy (NET), increasing chances for breast conserving surgery with less toxicity than neoadjuvant chemotherapy (NCT). A National Cancer Database study found that NET use increased by only 0.5% between 2004 and 2012. We investigated the utilization of NET, NCT, and no neoadjuvant therapy (no NT) from 2005 to 2023. We queried the TriNetX database for patients with HR + BC (stages I-III, ER+, PR+, ERBB2-) who underwent mastectomies in the US and evaluated utilization of NET, NCT, or no NT. We trended each use by all ages, age ≤ 50 years, or ≥ 51 years across roughly 5-year increments. NET cases were less than 10 for 2005-2009, and rounding obscured the exact count, so this period was excluded from the trend analysis. The use of NET remained below 1%, while NCT utilization was approximately 11%, and breast conserving surgery was achieved more frequently with NET than NCT (p < .0001). Both therapy types were used more frequently with advanced cancer stage (p < .0001), and NCT use was higher than NET in both age groups (p < .0001). NET and NCT use did not show significant trends when all ages were combined (p = .39). However, age-stratified analyses revealed significant declines in NCT use within each age group, with similar NET patterns and increasing no NT (p < .0001), indicating that overall results may mask weighted subgroup trends. This study highlights underutilization of NET, despite its low toxicity and efficacy in improving patient outcomes. Increased efforts are needed to address this gap and consider NET as an option for HR + BC.